Compare Capri Holdings Ltd (CPRI) vs Johnson & Johnson (JNJ) Price & Performance

CPRI trades at $14.68, up 1.66% today, with a bullish technical signal from moving averages. The stock has beaten EPS estimates in recent quarters, but faces fundamental headwinds with revenue declining to $4.44B in 2025 and a net loss of $1.18B. Analyst consensus is a $20.57 price target, with 44% buy ratings. Recent news highlights brand revitalization efforts and second-half growth expectations from management commentary at the Goldman Sachs conference.

The outlook balances low valuation multiples against operational challenges. Investment appeal lies in potential margin improvement and brand turnaround, but risks include sustained revenue weakness, high debt levels, and competitive pressures in the luxury sector. The stock's recovery hinges on execution of the Michael Kors reset and macroeconomic support for consumer discretionary spending.

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).

JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.